Explore the Agenda
7:30 am Check-In & Light Breakfast
8:20 am Programme Director’s Opening Remarks
8:25 am Chair’s Opening Remarks
Advancing Cardiometabolic Health: Redefining Obesity Therapeutics Through Multi-Organ Benefits & Value-Based Endpoints
8:30 am From Data to Impact: Real-World Evidence Transforming Obesity & Cardiometabolic Care
- Leveraging RWE to accelerate drug development with a lifecycle lens
- Exploring treat-to-target paradigms and patient-centric endpoints to enhance reimbursement potential
- Looking beyond trials by using RWE to identify high-risk populations and support precision medicine to accelerate market access
9:00 am Integrating Liver & Metabolic Improvements in Patient Weight Management
- Addressing co-morbidities in obese patients
- Evaluating Icosabutate: a liver targeted, modified long chain fatty acid to improve glycaemic control, hepatic inflammation and fibrosis in MASH patients
- Identifying synergy for potential combination therapy with icosabutate and GLP-1 agonists
9:30 am Roundtable Discussion: Redefining Cardiometabolic Endpoints as the New Gold Standard in Obesity Drug Development
Join this interactive roundtable to reshape how we measure and reward innovation in obesity therapeutics through cardiometabolic endpoints. As the field moves beyond weight loss alone, this session will bring together regulators, payers, clinicians, and patient advocates to align on new success metrics that reflect the full value of obesity treatments.
- Standardising evidence beyond BMI by aligning regulators and payers on multi-organ cardiometabolic benefits such as imaging data and body composition metrics as critical endpoints for approval and reimbursement
- Balancing clinical and patient priorities through trial designs that capture both hard outcomes like cardiovascular risk reduction and quality-of-life improvements in mobility and daily functioning
- Demonstrating compelling value to payers by modelling long-term economic benefits, including cost savings from comorbidity improvement in conditions like NAFLD and metabolic syndrome
- Exploring how RWE and comparator strategies can address fragmented EU HTA expectations, as well as what post-launch validation data payers are demanding
Advancing Combination Therapies Beyond GLP-1 Monotherapies to Preserve Lean Mass & Improve Body Composition
10:00 am Exploring Novel Multi-Targeted Approaches to Preserve Lean Mass & Enhance Metabolic Health in Obesity Therapy
- Reviewing the mechanistic rationale for multi-targeted therapies to achieve synergistic targeting of appetite suppression and muscle catabolism
- Comparing the analysis of body composition outcomes in recent trials to highlight trade-offs between fat loss efficacy, lean mass preservation, and tolerability
- Understanding the lessons from Phase 2 trials of multi-targeted obesity therapies to reveal practical challenges in dosing, patient adherence, and biomarker selection for body composition endpoints
10:30 am Extended Duration Myostatin Antibody for Enhanced Weight Loss Quality
- Extended half-life reduces dosing frequency and injection volume and improves patient experience
- Myostatin inhibition can minimise lean mass loss during weight loss on GLP-1s
- Precision targeting of additional TGF-beta superfamily members could enable further improvements in weight loss quality
11:00 am Morning Break
Advancing Combination Therapies Beyond GLP-1 Monotherapies to Preserve Lean Mass & Improve Body Composition – Continued
11:15 am Comparing Myostatin vs Activin A Inhibition to Understand Metabolic Trade-Offs for Obesity Combinations
- Comparing preclinical data on myostatin-only vs. dual myostatin/activin A inhibitors to increased understanding of differentiating factors
- Guiding pharmaceutical partnerships and clinical trial designs for combination optimisation
- Identifying outcomes for patient subset identification in clinical stages
11:45 am Panel Discussion: Redefining the Standard of Care Through Combination & Sequential Therapies with GLP-1
Join this session to explore how obesity trials and treatment paradigms must evolve with GLP-1 agonists as the new backbone therapy. Experts will debate optimal approaches for testing combinations and sequencing therapies, addressing critical questions about trial design, phenotypic targeting, and weight rebound mitigation.
- Determining patient-centric cardiometabolic endpoints to extend beyond weight loss while satisfying payer demands
- Combining dual GLP-1 and myostatin inhibitors to reduce muscle mass loss for greater metabolic health and explore composite endpoints that reflect real-world patient priorities to lower trial dropout rates
- Exploring sequential therapy protocols to reduce GI side effects for improved long-term adherence
- Reducing weight cycling by shifting focus from acute weight loss to sustained metabolic outcomes
12:30 pm Roundtable Discussion: Balancing Fat Loss, Muscle Preservation, & Metabolic Health to Optimise Combination Therapies
- Integrating myostatin/activin inhibitors with GLP-1 agonists to preserve metabolic health and enhance long-term patient outcomes
- Leveraging biomarkers & phenotyping to guide patient stratification for combination therapies to identify responders to specific mechanisms
- Designing adaptive trials for multi targeted therapies to enable dosing optimisation and combination ratios for improved efficacy and tolerability
Solving Manufacturing and Administration Challenges to Improve Adherence for Obesity Therapies & Lifelong Metabolic Health
1:00 pm From Peptides to Pills: The Oral Obesity Drug Revolution
- Highlight formulation challenges behind bioavailability and titration
- Predict market shifts if oral efficacy rivals injectables
- Discussing transition pipelines to small molecules to understand benefits and disadvantages of changing to different therapies
- Ensuring future portfolios against peptide production bottlenecks to reduce costs and unnecessary pollutants
1:30 pm Lunch
Solving Manufacturing & Administration Challenges to Improve Adherence for Obesity Therapies & Lifelong Metabolic Health – Continued
2:30 pm Improving Maintenance Strategies for Preventing Weight Rebound Post-Therapy to Improve Long-Term Patient Outcomes
- Understanding meal-triggered dosing that encourages conscious food choices to address weight rebound and aligns with lifelong metabolic health
- Revealing the benefits of safety-first approach to obesity therapies to avoid stringent monitoring, enabling broad long-term access for chromic management
- Unveiling EMP16’s modified release dual mechanism responsible for its proven safety and enhanced efficacy to provide a first-line cost-effective therapy
3:00 pm Panel Discussion: Looking to the Future for the Obesity Field
- Considering lifelong metabolic health for maintenance therapies beyond GLP-1s for better long term patient outcomes
- Identifying driving factors of meal-triggered dosing and behavioural reinforcement strategies to improve long-term outcomes by fostering metabolic health
- Exploring body composition and biomarkers as a gateway to improving life-long cardiometabolic health